pre-IPO PHARMA

COMPANY OVERVIEW

Transcenta is a clinical stage global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. Transcenta has established global footprint, with Headquarter and Discovery and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Beijing, Shanghai and Guangzhou in China and in Princeton, US, and External Partnering Center in Boston, US. Transcenta is developing a panel of nine antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Upon the latest financing, the company has raised over $342 million from globally prominent investors.


LOCATION

  • Suzhou, None, China
  • Shanghai, None, China
  • Hangzhou, None, China
  • Beijing, None, China
  • Waltham, MA, USA
  • Princeton, NJ, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Oncology

  • WEBSITE

    https://www.transcenta.com/


    CAREER WEBSITE

    https://www.transcenta.com/careers/Experienced_Professionals


    SOCIAL MEDIA


    INVESTORS

    arch-venture-partners china-capital china-equity-group china-merchants-capital china-structural-reform-fund country-garden-venture-capital crcp epiphron-capital fortune-capital hillhouse-capital kingstar-capital lilly-asia-ventures qatar-investment-authority, sequoia-capital-china taikang temasek teng-yue-partners


    PRESS RELEASES


    Mar 29, 2023

    Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer


    Mar 22, 2023

    Transcenta to Present Two Preclinical Studies at AACR 2023 USA - English APAC - English


    Mar 22, 2023

    Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors USA - English APAC - English


    Jan 17, 2023

    Transcenta to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer


    Jan 3, 2023

    Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors


    For More Press Releases


    Google Analytics Alternative